Muvalaplin shows promise in lowering Lp(a) levels in clinical trial
A clinical trial testing muvalaplin, a novel oral medication, demonstrated safe and effective reduction of high lipoprotein(a) levels by up to 85.5%, according to late-breaking science presented at the American Heart Association's Scientific Sessions 2024.